UK drug industry Code of Practice changes announced
The Association of the British Pharmaceutical Industry has published details of changes to its Code of Practice, effective from July 1 (Marketletter April 14). As previously reported, the changes bring the ABPI's rules for relationships with patient groups into line with the new European Federation of Pharmaceutical Industries and Associations' rules (Marketletter November 26, 2007). In addition, stricter limits on the supply of drug samples are imposed.
Chris Brinsmead, the ABPI's president who took office on May 1, said: "the ABPI Code of Practice is continually evolving to ensure that the pharmaceutical industry and its stakeholders can have maximum confidence in the standards set for ethical and responsible behavior of companies and staff."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze